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ABSTRACT 
Background: Ganoderma lucidum is a type of fungus commonly consumed in Asia for the 
promotion of health and longevity. The observed biological activity of G. lucidum includes 
anti-cancer  and  anti-inflammatory  effects  which  may  be  useful  in  the  treatment  and 
prevention of cancer and other chronic diseases. G. lucidum grows under conditions which 
range  from  tropical  to  temperate  and  has  a  different  physiology  depending  on  the 
geographical region in which it is grown. For this reason, the health benefits may vary 
depending on the form of G. lucidum and the environmental conditions to which it was 
exposed.  This  led  us  to  investigate  the  effect  of  wildly  grown  G.  lucidum,  from  the 
Himalayan region versus other commercially available G. lucidum products, on two human 
cancer cell lines. 
 
Methods: Extraction of the bioactive components found in G. lucidum is essential, as the 
fungus  is  tough  and  indigestible.  Four  different  Ganoderma  extracts  were  prepared. 
Thereafter, the extracts were tested on two human prostate cancer cell lines, and the IC50s 
were determined. This was followed by the use of Affymetrix GeneChip® PrimeView™ 
Human  Gene  Expression  Arrays  to  identify  the  changes  in  gene  expression  due  to  the 
treatment of prostate cancer cell lines (PC3 and DU145) with Ganoderma extracts. Several 
key genes identified with Affymetrix analysis were validated using RT-PCR.  
 
Results  and  Discussion:  We  found  that  all  the  Ganoderma  extracts  showed  growth 
inhibition  in  the  cancer  cell  lines  tested.  Using  Affymetrix  microarray  analysis,  we 
identified  four  main  biologically  active  pathways:  cell  cycle  control/apoptosis,  cell-cell 
adhesion, DNA repair, and inflammatory /immune response, where activity was influenced Functional Foods in Health and Disease 2014; 4(5):182-207   Page 183 of 207 
by the Ganoderma extracts used. Using RT-PCR, we tested ten genes associated with all 
four pathways. The RT-PCR results supported our findings in the Affymetrix analysis, i.e. 
that G. lucidum extracts have an anti-inflammatory and cell cycle effect and therefore may 
have long term health benefits. These effects were specific to the extract tested. 
 
Key Words: Ganoderma lucidum, PC3, DU145, gene expression, Affymetrix, pathways, 
RT-PCR 
 
BACKGROUND 
Ganoderma lucidum (G. lucidum), commonly called Lingzhi in China, Reishi or Sachitake 
in Japan, and Youngzhi in Korea, is a large, dark fungus with a glossy exterior and a woody 
texture [1]. G. lucidum grows under a range of conditions and distinct forms grow in diverse 
geographical  regions  including  North  America,  Asia,  and  sub-Asia  continents  [2].  This 
fungus generally occurs in two growth forms: one found in North America, which is sessile 
and large with a reduced stalk; whilst the other is smaller and has a long, narrow stalk [2]. 
The latter is found mainly in the tropics and is the form used in this study. 
Owing to the numerous health benefits associated with the consumption of G. lucidum, 
there is a high demand for this fungus in parts of Asia. In order to meet growing demands, 
cultivation  has  become  a  major  industry.  Artificial  cultivation  of  G.  lucidum  has  been 
achieved  using  substrates  such  as  grain,  sawdust,  wood  logs,  and  cork  residues  [2].  It 
remains to be seen whether the growth conditions influence the reported health properties of 
this fungus. 
For  centuries  G.  lucidum  has  been  used  for  the  general  promotion  of  health  and 
longevity  in  Asian  countries  [1,  3].  It  has  been  recorded  as  having  numerous 
pharmacological effects, such as immuno-modulating, anti-inflammatory, analgesic, chemo-
preventive, anti-tumour, radio-protective, anti-viral, anti-oxidative and radical-scavenging, 
and anti-aging effects [4]. Studies have shown that G. lucidum can significantly improve a 
number of health and gerontology-related problems [2, 4, 5]. 
There are two main bioactive ingredients that are likely to contribute to the anti-cancer 
properties of G. lucidum: polysaccharides, which are extracted using a water based method, 
and triterpenes, which can be extracted using an ethanol based method [6].  
Both G. lucidum polysaccharides and triterpenes, in the form of Ganoderic acids, have 
been shown to modulate and improve immune function in human and mouse models [7, 8, 
9], due to increased survival of immune cells related to both innate- and adaptive-immunity 
[10,  11].  These  extracts  can  also  be  used  to  enhance  anti-tumour  immune  response  by 
promoting the activity of natural killer cells, cytotoxic T-lymphocytes [12], as well as boost 
antigen presentation, which is crucial for viral and cancer immunity [13]. Extracts from G. 
lucidum have shown carcinostatic effects in a wide variety of cancer cell lines, including 
those of the breast, pancreas, lung, colon, skin, and prostate [2]. These biologically active 
components can affect various biological pathways associated with the survival, progression, 
and  metastasis  of  tumours.  The  identification  of  the  bioactive  components  and  their 
associated anti-cancer activities in G. lucidum present Ganoderma as a potential therapeutic 
agent for the treatment and prevention of cancer. 
In  addition  to  its  potential  use  as  an  anti-cancer  agent,  G.  lucidum  may  also  be 
beneficial in conjunction with other anti-cancer therapies. One of the main drawbacks of a 
number of different anti-cancer therapies is the associated side-effects. Radiotherapy, used Functional Foods in Health and Disease 2014; 4(5):182-207   Page 184 of 207 
in the treatment of some cancers, can cause damage to adjacent, non-target, healthy tissues. 
G. lucidum, as well as having carcinostatic effects, has shown radio-protective effects in 
normal cells via the prevention of DNA damage induced by radiation [14]. In addition, G. 
lucidum  has  been  shown  to  enhance  the  recovery  of  cellular  immune-competence  from 
gamma–irradiation  [15,  16].  The  observed  radio-protective  effects  both  in  in  vitro  and 
animal  studies  suggest  that  G.  lucidum  may  reduce  the  adverse  side-effects  caused  by 
radiotherapy. G. lucidum also has the potential to help reduce the toxicity and undesirable 
side-effects  from  common  cancer  chemotherapies,  such  as  Cisplatin  [17],  and  could 
therefore play a major role in combination therapy with cancer treatments to not only reduce 
anti-oxidant effects but to act synergistically as well [17, 18]. G. lucidum, when used in 
combination with various well-established cancer therapies, is shown to reduce the adverse 
side  effects  associated  with  anti-cancer  therapies  [19].  The  fact  that  G.  lucidum  is 
carcinostatic and lacks any observable side-effects [19] makes it an ideal candidate to be 
used as a natural remedy for the treatment of various forms of cancer, including cancer of 
the lung, breast, colon, and prostate.  
In this study, we have prepared several Ganoderma extracts and used a comprehensive 
transcriptomic  analysis  (Affymetrix  GeneChip®  PrimeView™  Human  Gene  Expression 
Arrays) to identify the critical genes and pathways associated with the biologically active 
ingredients of G. lucidum. Analyses of these changes in gene expression have identified 
several  major  biological  pathways  associated  with  the  potential  health  benefits  of  the 
Ganoderma extracts including anti-cancer and anti-inflammatory effects. In addition, we use 
real time - polymerase chain reaction (RT-PCR), to confirm some of our findings in the 
Affymetrix gene expression analysis. 
 
METHODS:  
Materials: The dried fruiting bodies of wild G. lucidum were provided by NZFOCUS (NZ) 
Ltd. All chemicals and reagents were from Sigma-Aldrich Co., unless indicated. 
 
Preparation of G. lucidum extracts: A total of four Ganoderma extracts were tested in this 
study; these were:  Ganoderma water extract,  Ganoderma ethanol extract,  GanoPoly®C
+ 
(ENCORE International ltd.), and Ganoderma spore oil (Xianzhilou Biological Science & 
Technology  Co.,  Ltd.)  extract.  Their  properties  and  extraction  processes  are  described 
below: 
 
Ganoderma  water  extracts:  Hot  water  extraction  of  G.  lucidum  is  the  most  widely 
employed traditional method for extracting the active ingredients of G. lucidum [2]. Ten 
grams of G. lucidum were cut into 0.5 to 1 cm pieces and extracted using the water-based 
method as outlined by Lu et al. [20]. 
 
Ganoderma ethanol extracts: Studies have shown that extraction of G. lucidum with an 
ethanol solvent yielded the highest amount of triterpenes, including Ganoderic acids [21, 
22]. Ten grams of G. lucidum were cut into 0.5 to 1 cm pieces and extracted using an 
ethanol based method as outlined by Lakshmi et al. [23]. 
 
Ganopoly®C
+,  hereafter  abbreviated  as  Ganopoly,  is  a  commercially  available  health 
supplement. Each capsule contained 500 mg of Ganopoly powder concentrated from 27.5 g Functional Foods in Health and Disease 2014; 4(5):182-207   Page 185 of 207 
of  dry  G.  lucidum  [8,  9].  The  Ganopoly  powder  was  dissolved  in  Dimethyl  Sulfoxide 
(DMSO) to give a concentration of 110.7 mg/ml (Ganopoly powder). Thus 110.7 mg/ml 
Ganopoly solution was equivalent to 6088 mg/ml of dry G. lucidum fruit. 
 
Ganoderma  spore  oil:  Spore  oil  softgel  is  marketed  in  China  as  an  over-the-counter 
product for general health improvement. According to the manufacturer, each soft gel pill 
contained 100 mg of Ganoderma spore oil. The spore oil was dissolved in DMSO to give a 
concentration of 0.2 mg/ml. 
 
Azathioprine: (Sigma Chemical Company) was used as a positive control for assessing 
growth inhibitory potential of the Ganoderma extracts. Azathioprine is a known drug used 
for the treatment of childhood acute leukaemia which acts by suppressing cell proliferation 
via inhibition of DNA synthesis [24, 25]. 
 
Cell lines: Human prostate cancer (PCa) cell lines PC3 and DU145 were provided by 
the Auckland Cancer Society Research Centre. Both cell lines were grown in media 
consisting  of  Minimum  Eagle  Media  +  10%  Fetal  Calf  Serum  +  1%  of 
Penicillin/Streptomycin / Glutamine. The cells were grown in 25 ml Becton Dickinson 
Falcon™ cell culture flasks (BD Biosciences) at 37°C with 5% CO2. 
Growth inhibitory assay 
The cells were harvested when they reached 90% confluence. All cell lines were seeded 
at  a  cell  density  of  2000  cells/well  in  the  experimental  96-well  plates  and  incubated 
overnight at 37°C with 5% CO2 before treating with the extracts. The cells were incubated 
under the same condition for four doubling cycles. Growth inhibition was measured using 
the Sulforhodamine B based assay [26]. Using results from the growth inhibition assays, the 
optimal dosing range was determined. Standard curve analysis was performed using Sigma 
plot 11.0 (Systat Software Inc.) and the IC50 values of each extract in each cell line were 
determined using the standard curve. 
 
RNA extraction: The cells were treated with the various extracts at the established IC50, 
and the RNA was isolated using an RNeasy Plus Mini Kit (QIAGEN). The concentration 
and  purity  of  the  RNA  samples  was  assessed  using  a  NanoDrop®  ND-1000 
Spectrophotometer  (Thermo  Fisher  Scientific),  as  well  as  via  Experion  RNA  Standard 
Sensitive (StdSen) Analysis (Bio-Rad) [27, 28]. The Affymetrix GeneChip® PrimeView™ 
Human Gene Expression analysis required RNA samples with high integrity, namely an 
RNA quality index of >8. 
 
Gene  expression  analysis:  The  Affymetrix  GeneChip®  PrimeView™  Human  Gene 
Expression Arrays were used to measure the gene expression profile of selected cancer cell 
lines after treatment with various extracts. It is capable of measuring the expression of more 
than 20,000 genes using 530,000 probes covering 36,000 transcripts and their variants [29, 
30]. A total of eight extracts (including positive and negative controls) were tested in PC3 
and DU145. Three technical replicates were analysed per extract per cell line, resulting in a 
total of 48 samples submitted for Affymetrix analysis to be completed at the Ramaciotti 
Centre, University of New South Wales, Sydney, Australia. Functional Foods in Health and Disease 2014; 4(5):182-207   Page 186 of 207 
Affymetrix array data were analysed using the packages of ‘affy’ and ‘limma’ in R [31]. 
Correction for multiple testing was carried out using Benjamini–Hochberg false-discovery 
rate [31].  
 
Pathway analysis: The data was selected based on statistical significance and strength of 
association with extracts. The process of data selection is summarized in Figure 1. The 
Affymetrix analysis generated raw absorbance data for the 530,000 probes used.  
 
 
Figure 1. Overview of Affymetrix Genechip
® PrimeView
TM array data analysis. Data 
analysis process used to identify significant genes for GATHER pathway analysis utilizing 
the  raw  data  generated  by  Affymetrix  analysis.  The  fold  change  and  p-values  were 
calculated from raw data. Only genes with a fold change of three or greater and a p-value of 
less than 0.01 were selected. The selected genes were input into GATHER and a list of 
biologically active pathways was generated. GATHER = Gene Annotation Tool to Help 
Explain Relationships. 
 
A p-value of 0.01 was chosen as the cut off point for statistical significance. Genes with 
a fold change of greater than three, regardless of whether they were up- or down-regulated, 
were  selected  for  pathway  analysis  using  Gene  Annotation  Tool  to  Help  Explain 
Relationships  (GATHER).  The  selected  genes  from  each  extract  per  cell  line  were 
submitted  to  GATHER  separately  to  find  Gene  Ontology  annotations.  GATHER 
(http://gather.genome.duke.edu/) is a gene annotation tool which examines the relationships 
between genes. GATHER generates a list of biological pathways associated with the genes 
submitted, and ranks them based on Bayes factor. The Bayes factor represents the strength 
of association between the list of genes submitted and the biological pathway based on the Functional Foods in Health and Disease 2014; 4(5):182-207   Page 187 of 207 
Gene Ontology Database. The higher the Bayes factor value, the stronger the association 
[32]. 
 
RT-PCR: The RNA was converted to cDNA using a Quantitect Reverse Transcription Kit 
(QIAGEN).  The  genes  of  interest  were  amplified  with  relevant  primers  available  from 
Invitrogen as shown in Table 1.  
 
Table 1. List of selected genes and their respective RT-PCR assay IDs with target 
chromosome locations. For each RT-PCR assay, the closest probe (based on chromosome 
location) in the Affymetrix array analysis is also listed. 
 
 
RT-PCR analysis  Affymetrix array analysis 
Gene  Assay ID  Chromosome location  Probe ID 
Chromosome 
location 
BRCA1  Hs01556193_m1 
Chr.17: 41196312 - 
41277500 
11744317_x_at 
chr17:41196311-
41277468 
CDH11  Hs00901475_m1 
Chr.16: 64980683 - 
65155919 
11749461_a_at 
chr16:64980684-
65155930 
CDKN3  Hs00193192_m1 
Chr.14: 54863673 - 
54886936 
11730821_x_at 
chr14:54863672-
54886936 
COL11A1  Hs01097664_m1 
Chr.1: 103342023 - 
103574052 
11733706_s_at 
chr1:103342028-
103574052 
IFITM1  Hs00705137_s1 
Chr.11: 313991 - 
315272 
11715670_a_at 
chr11:313526-
315272 
IL1α  Hs00174092_m1 
Chr.2: 113531492 - 
113542971 
11725198_at 
chr2:113531501-
113542971 
IL24  Hs01114274_m1 
Chr.1: 207070788 - 
207077484 
11741775_a_at 
chr1:207070788-
207077484 
IRF1  Hs00971960_m1 
Chr.5: 131817301 - 
131826465 
11716733_at 
chr5:131816674-
131826475 
MCM7  Hs00428518_m1 
Chr.7: 99690404 - 
99699427 
11752905_a_at 
chr7:99690403-
99698981 
RAD51  Hs00153418_m1 
Chr.15: 40987327 - 
41024356 
11734841_a_at 
chr15:40987357-
41024504 
S100A9  Hs00610058_m1 
Chr.1: 153330330 - 
153333503 
11716523_at 
chr1:153330329-
153333503 
 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a house-keeping gene 
for normalization of RNA expression. PCR was performed with a thermocycler (Applied 
Biosystems),  and  the  amplified  products  were  quantified  using  TaqMan®  probes 
(Invitrogen). For each experimental setup, a standard curve was calculated with SDS2.3 
software  from  three  technical  repeats.  Two  biological  repeats  were  made.  The  relative 
expression was calculated using Microsoft Excel 2010 as fold change between extracts-
treated cell lines versus untreated controls, for comparison with Affymetrix results.  
 
RESULTS 
The growth-inhibitory properties and the resulting changes in  gene expression levels of 
various extracts of G. lucidum on two human cancer cell lines were investigated. Functional Foods in Health and Disease 2014; 4(5):182-207   Page 188 of 207 
Growth inhibition of the prostate cancer cell lines: PC3 and DU145 are two cell line 
models of human PCa. Growth inhibition of the Ganoderma extracts and Azathioprine used 
to treat PC3 and DU145 were calculated from dose response curves and are shown in Table 
2. All extracts showed positive dose-response curves supporting the claim that increased 
dosage of the extracts resulted in decreased cell survival. 
 
Table 2. Growth inhibition of PC3 and DU145 versus concentration of Ganoderma extracts 
and Azathioprine. 
 
 
Growth Inhibition 
(mg/ml) 
Extracts  PC3 IC50 
DU145 
IC50 
Ganoderma water 
extract 
7.95  12.44 
Ganoderma ethanol 
extract 
0.217  0.132 
Ganopoly  0.222  0.334 
Spore oil  7.15E-04  6.72E-04 
Azathioprine  7.90E-04  9.71E-04 
 
Ganoderma spore oil extract had the lowest dosage required for 50% growth inhibition, 
followed by Azathioprine, Ganoderma ethanol extract, and Ganopoly. Ganoderma water 
extract  required  the  highest  concentration  to  reach  IC50.  The  same  trend  applied  for 
Ganoderma ethanol extract, Ganopoly, and Ganoderma water extract at IC70 and IC90.  
 
Biological pathways: A list of biological pathways, generated by GATHER, associated with 
Ganoderma ethanol extract and spore oil in PC3 and DU145 are shown in Table 3. A list of 
biological pathways associated with Ganoderma water extract and Ganopoly in PC3 and 
DU145 are shown in Table 4. Many of the identified pathways are interrelated. For example, 
the significant genes from the treatment of DU145 with Ganoderma ethanol extract were 
associated with pathways such as “regulation of cell cycle,” “mitotic cell cycle,” and “cell 
cycle  checkpoints,”  which  were  all  associated  with  cell  cycle  and  proliferation.  The 
biological pathways identified by GATHER were further grouped into associated biological 
functions.  The  Bayes  factor  was  used  to  determine  the  statistical  significance  of  the 
biological  pathways.  A  Bayes  factor  of  greater  than  two  is  considered  statistically 
significant [32]. 
Ganoderma ethanol extract and spore oil extract treatment of PC3 and DU145 resulted 
in significant changes in the expression of genes associated with cell cycle and apoptosis, as 
shown in Table 3. A comparison of the two ethanol-based extracts across PC3 and DU145 
cell lines showed that DU145 treated with Ganoderma ethanol has the greatest number of 
genes associated with cell cycle and apoptosis. Pathways associated with DNA repair, DNA 
replication,  and  cell-cell  adhesions  are  also  found  to  be  associated  with  treatment  with 
Ganoderma ethanol-based extracts. 
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Table 3. A list of biological pathways associated with Ganoderma ethanol-based 
extracts in PC3 and DU145. 
Biological Pathways 
PC3  DU145 
Ganoderma 
ethanol extract  spore oil 
Ganoderma 
ethanol extract  spore oil 
No.of 
Genes 
Bayes 
factor 
No.of 
Genes 
Bayes 
factor 
No.of 
Genes 
Bayes 
factor 
No.of 
Genes 
Bayes 
factor 
Cell Cycle 
cell proliferation  47  88  239  369  225  336  127  201 
cell cycle  47  107  234  457  218  410  123  239 
regulation of cell cycle  28  57  129  225  125  217  70  123 
negative regulation of 
cell proliferation 
4  2  18  10  22  18  9  6 
mitotic cell cycle  32  94  81  157  65  109  46  90 
cell cycle checkpoint  9  27  21  47  18  37  16  37 
G1 phase of mitotic cell 
cycle 
2  2  7  9  6  6  4  4 
G1/S transition of 
mitotic cell cycle 
7  15  23  39  22  37  16  31 
G2/M transition of 
mitotic cell cycle 
9  24  20  36  16  24  13  25 
M phase of mitotic cell 
cycle 
25  75  59  116  44  72  31  59 
mitotic checkpoint  5  17  11  32  8  17  6  14 
Apoptosis 
cell death  10  6  70  60  72  65  38  33 
programmed cell death  10  6  70  64  71  67  37  34 
regulation of 
programmed cell death 
9  9  64  87  66  94  36  51 
regulation of apoptosis  9  9  64  88  66  95  36  51 
apoptosis  10  7  70  64  71  68  37  34 
positive regulation of 
programmed cell death 
4  2  35  47  37  53  22  32 
positive regulation of 
apoptosis 
4  2  35  47  37  53  22  33 
induction of 
programmed cell death 
4  2  32  41  36  50  21  31 
induction of apoptosis  4  2  32  41  35  50  21  31 
DNA 
repair and 
replication 
DNA repair  5  3  37  39  32  30  15  11 
DNA damage checkpoint  2  3  5  6  6  10  5  10 
mismatch repair  -  -  6  4  5  2  -  - 
DNA replication and 
chromosome cycle 
11  17  71  130  57  90  34  56 
DNA replication  7  8  58  108  50  85  28  47 
DNA-dependent DNA 
replication 
5  7  30  53  27  44  13  18 
Cell-cell 
adhesion 
cell-cell adhesion  7  2  3  2  17  5  7  3 
homophilic cell adhesion  5  2  3  2  16  8  9  3 
 
Both Ganoderma water extract and Ganopoly treatment of PC3 cells showed significant 
changes in gene expression associated with immune and inflammatory response, as shown 
in  Table  4.  Treatment  with  Ganopoly  showed  biological  pathways  associated  with  cell 
cycle, apoptosis, and angiogenesis in both PC3 and DU145 cell lines. Functional Foods in Health and Disease 2014; 4(5):182-207          Page 190 of 207 
 
Table 4. A list of biological pathways associated with Ganoderma water-based extracts in 
PC3 and DU145. 
 
Biological Pathways 
DU145  PC3 
No. of 
Genes 
Bayes 
factor 
No. of 
Genes 
Bayes 
factor 
Ganoderma water extract 
Immune and 
inflammatory 
response 
regulation of cellular process  24  8  11  2 
response to biotic stimulus  28  9  27  6 
immune response  22  6  25  8 
defence response  24  7  26  7 
Ganopoly 
Immune and 
inflammatory 
response 
immune response  19  26  25  42 
defence response  19  24  25  39 
inflammatory response  4  2  5  4 
Cell Cycle 
cell proliferation  21  25  18  17 
regulation of cell proliferation  10  15  12  16 
cell cycle  15  17  13  11 
regulation of cell cycle  12  16  8  10 
cell cycle arrest  4  7  4  6 
G2/M transition of mitotic cell cycle  3  4  3  4 
G1/S transition of mitotic cell cycle  3  4  3  3 
Apoptosis 
cell death  10  10  11  12 
programmed cell death  10  10  11  12 
regulation of programmed cell death  6  5  9  12 
regulation of apoptosis  6  5  9  12 
apoptosis  10  10  11  12 
negative regulation of programmed cell 
death 
3  2  5  7 
negative regulation of apoptosis  3  2  5  7 
Angiogenesis 
blood vessel development  3  4  3  4 
blood vessel morphogenesis  3  4  3  4 
angiogenesis  3  4  3  4 
 
Four  biologically  active  pathways  have  been  identified  as  the  result  of  Affymetrix 
analysis.  The  first  is  the  cell  cycle  associated  pathways.  Genes  associated  with  cell 
proliferation,  cell  cycle,  and  apoptosis  were  found  to  have  significant  changes  in  their 
expression levels after treatment with Ganoderma ethanol extract, spore oil, and Ganopoly 
in both PC3 and DU145 cell lines. Cell cycle control and apoptosis are two closely linked 
biological pathways [33, 34]. Expression of genes which promote or are associated with 
apoptosis are up-regulated, and expression of genes that inhibit apoptosis or are associated 
with reduced apoptosis are down-regulated. Genes associated with DNA repair and cell-cell 
adhesion were also found to be up-regulated with treatment of Ganoderma ethanol extract 
and spore oil in both cell lines. Genes associated with immune and inflammatory responses 
were found to be associated with treatment of Ganoderma water extract and Ganopoly in 
PC3 and DU145. Genes associated with angiogenesis were found to be associated with 
Ganopoly treatment only. Functional Foods in Health and Disease 2014; 4(5):182-207          Page 191 of 207 
 
Key genes: We have identified several key genes based on gene expression levels. Their 
significance to biological pathways associated with inflammation and PCa is supported by 
the  literatures.  Genes  include:  Cyclin-dependent  kinase  inhibitor  3  (CDKN3),  RAD51, 
Cadherin 11, type 2 (CDH11), Collagen, type XI, alpha 1 (COL11A1), and Breast Cancer 
type 1 (BRCA1) in Ganoderma ethanol extract and Ganoderma spore oil extract, and the 
gene expression levels of S100 calcium binding protein A9 (S100A9), interferon induced 
transmembrane protein 1 (IFITM1), interleukin 24 (IL24), interleukin 1-alpha (IL1α), and 
interferon regulatory factor 1 (IRF1) in Ganoderma water extract and Ganopoly in PC3 and 
DU145 cell line. 
Figure 2 shows a list of genes with significant changes in their expression levels after 
cell culture treatment with Ganoderma ethanol extract and spore oil extract.  
Fold changes were calculated by carrying out a comparison between the extracts and 
media control, adjusted for their respective solvents (DMSO for spore oil and ethanol for 
Ganoderma  ethanol  extract).  Only  sample-treatment  combinations  with  statistically 
significant  adjusted  p-values  (p  <  0.05)  are  shown.  Empty  blocks  represent  sample-
treatment combinations with non-significant changes in gene expression. 
 
Figure 2. The changes in gene expression of key genes associated with Ganoderma-
ethanol based extracts. Genes associated with cell cycle and proliferation based on the results 
from the Affymetrix gene expression analysis. Probes with an adjusted p-value of > 0.05 are 
excluded. Up-regulated probes are highlighted in red and down-regulated probes are highlighted in 
green. 
 
For  cells  treated  with  Ganoderma  ethanol  and  spore  oil  extract,  the  expression  of 
BRCA1,  RAD51,  and  CDKN3  are  up-regulated.  For  BRCA1  and  CDKN3,  Ganoderma 
ethanol extract induced a greater increase in gene expression than spore oil in both PC3 and Functional Foods in Health and Disease 2014; 4(5):182-207          Page 192 of 207 
 
DU145 cell line. For RAD51, spore oil induced a greater increase in gene expression than 
Ganoderma ethanol. 
The expression of CDH11 was up-regulated in the PC3 cell line, but the changes were 
not  significant  in  DU145. The  expression levels  of  COL11A1 were significantly  down-
regulated only in the PC3 cell line, but not in the DU145 cell line. 
Figure 3 shows the top 50 genes with the greatest changes in gene expression levels 
after administration of Ganoderma ethanol-based extract. Five pathways are shown. Most 
genes are associated with cell cycle control, as DNA replication and Mitosis are part of the 
cell cycle process. Fourteen genes are associated with regulation of apoptosis and three 
overlap with cell cycle associated pathways. Five genes are associated with homophilic cell 
adhesion and one overlaps with cell cycle. 
 
 
Figure 3. Genetic interactions of the top 50 genes associated with Ganoderma ethanol-
based  extracts. Using the result from Affymetrix analysis, the top  50 genes with the greatest 
changes in gene expression associated with Ganoderma ethanol-based extracts in PCa cell lines were 
selected. These genes were selected from a pool of genes with fold change of three or greater and a 
p-value of less than 0.01. The 50 genes were inputted into GeneMANIA to identify the genetic 
interactions. The genes were further grouped based on their associated pathway(s). 
 
Figure 4 shows a list of genes associated with significant changes in their expression 
levels following administration with Ganoderma water extract and Ganopoly. Fold change 
was calculated by the comparison between the extracts and media control adjusted for their 
respective  solvents  (DMSO  for  Ganopoly).  Only  probes  with  statistically  significant 
adjusted p-values (p < 0.05) are shown, with empty blocks representing samples with non-
significant changes in gene expression. Functional Foods in Health and Disease 2014; 4(5):182-207          Page 193 of 207 
 
The expression of S100A9 is down-regulated in both cell lines. The expression of IL1α 
is down-regulated in PC3 and DU145 treated with Ganopoly and Ganoderma water extract. 
The expression of IL24 and IRF1 is up-regulated after treatment with Ganopoly in both cell 
lines. The expression of IL24 and IRF1 is also up-regulated in the PC3 cell line treated with 
Ganoderma water extract.  IFITM1 expression is  down-regulated in DU145 treated with 
Ganopoly and Ganoderma water extract and up-regulated in PC3 treated with the same  
extracts. 
 
Figure 4. The changes in gene expression of key genes associated with Ganoderma-
water based extracts. Genes associated with immune response and inflammation based on the 
result  of  Affymetrix  gene  expression  analysis.  Probes  with  an  adjusted  p-value  of  >  0.05  are 
excluded. Up-regulated probes are highlighted in red and down-regulated probes are highlighted in 
green. 
 
Figure 5 shows the top 50 genes with the greatest changes in gene expression levels 
after administration of Ganoderma water-based extract. Four pathways are shown. Over half 
of the top genes are associated with immune/inflammation pathways. There are 20 genes 
associated with cell proliferation, 12 genes are associated with apoptosis, and four genes are 
associated  with  angiogenesis.  Each  pathway  contains  gene(s)  that  overlap  with  other 
pathways. In addition, IL8 is involved in all four pathways. 
 
RT-PCR: Two biological repeats and three technical repeats were performed per sample-treatment 
combination. 
 
Cycle threshold of GAPDH and selected genes in RT-PCR: The Ct in the amplification 
plot was checked to ensure that it intersected the linear portion of the amplification curve. 
The  plateau  suggested  the  depletion  of  the  TaqMan®  probe,  which  prevented  further 
increase  in  fluorescent  intensity.  Therefore,  at  the  plateau,  the  fluorescent  intensity  no 
longer reflects the level of PCR product. The absorbance value at the Ct was generated. An 
amplification plot of GAPDH (Figure 6a) showed the Ct ranges between 16 and 26. In the 
amplification plot with all gene primers (Figure 6b), the smallest Ct is 21 and highest Ct is 
25.3 which both lie between 16 and 26. 
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Figure 5. Genetic interactions of the top 50 genes associated with Ganoderma water-
based  extracts. Using the result from Affymetrix analysis, the top 50 genes with the greatest 
changes in gene expression associated with Ganoderma water-based extracts in PCa cell lines were 
selected. These genes were selected from a pool of genes with fold change of three or greater and a 
p-value of less than 0.01. The 50 genes were inputted into GeneMANIA to identify the genetic 
interactions. The genes were further grouped based on their associated pathway(s). 
 
 
Figure 6. RT-PCR amplification plots from the PC3 cell line treated with media. (a) 
Amplification plot of fluorescent profile of GAPDH housekeeping gene with the VIC® detector. (b) 
Amplification plot of the fluorescent profiles of the 11 selected genes with FAM™ detector. Functional Foods in Health and Disease 2014; 4(5):182-207          Page 195 of 207 
 
RT-PCR comparison with Affymetrix gene expression results: A comparison of the fold 
changes in gene expression between RT-PCR and Affymetrix analysis is shown in Figures 7 
and 8. The changes in gene expression were normalized with media control and expressed 
as fold change. Positive values for fold change represent up-regulation of gene expression 
while negative values represent down-regulation. Overall, RT-PCR and Affymetrix showed 
similar gene expression trends. Expression levels of IRF1 and IL24 are higher in RT-PCR 
analysis than Affymetrix in Ganoderma water and Ganopoly respectively (Figure 7). The 
gene expression levels of CDKN3, RAD51, and BRCA1 are also higher in RT-PCR than the 
Affymetrix analysis after treatment with Ganoderma ethanol (Figure 8). 
 
 
 
Figure 7. Comparison of gene expression levels measured by RT-PCR and Affymetrix. 
Comparison  of  the  changes  in  gene  expression  levels  after  treatment  with  Ganoderma 
water-based extracts between RT-PCR and Affymetrix analysis in DU145 and PC3 cell 
lines. The probes for IL1α had failed to amplify in DU145 cell line and are excluded from 
the figure. IL1α = interleukin 1-alpha. 
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Figure 8. Comparison of gene expression levels measured by RT-PCR and Affymetrix. 
Comparison of the changes in gene expression levels after treatment with Ganoderma ethanol-based 
extracts between RT-PCR and Affymetrix analysis in DU145 and PC3 cell lines. The probes for 
CDH11  had failed to  amplify  in  DU145  cell line and  are  excluded from  the  figure.  CDH11  = 
Cadherin 11, type 2. 
 
DISCUSSION 
The development of cancerous cells is a multistep process involving normal cells acquiring 
several hallmarks of cancer to evolve to a neoplastic state. These biological capabilities of 
malignant cells can be targeted for the treatment of cancer. Treatment with Ganoderma-
based extracts resulted in changes in the gene expression levels of a number of genes. The 
use of an Affymetrix array has permitted characterization of the expression levels of large 
numbers  of  genes  simultaneously.  This  allowed  the  examination  and  discovery  of 
biologically active pathways associated with the anti-cancer activity of G. lucidum. 
 
Cell  cycle  control  and  proliferation:  Treatment  of  PC3  and  DU145  cancer  cells  with 
Ganoderma extracts containing triterpenes (Ganoderma ethanol extract and spore oil extract) 
resulted in changes in gene expression associated with cell proliferation and regulation of 
cell cycle. One of the hallmarks of cancer is the deregulation of cellular proliferation [35]. 
The cell cycle is a process cells undergo in order to divide and proliferate, and various 
successful anti-cancer drugs act by inhibiting the cell cycle [36]. In addition, expression of 
genes associated with mitosis was also affected. Mitosis is a critical and highly regulated 
step in the cell cycle. Mitosis regulates the division and passage of genetic information from Functional Foods in Health and Disease 2014; 4(5):182-207          Page 197 of 207 
 
one cell generation to the next. Errors in mitosis can lead to uncontrolled proliferation and 
culmination  of  genetic  instability,  which  can  further  promote  cancer  development  [37]. 
Since cancer cells are rapidly dividing cells which constantly undergo mitosis, anti-cancer 
drugs targeting mitosis have the potential to be highly selective and sensitive. Current anti-
mitotic drugs cannot completely eradicate cancer cells, and are often associated with not 
only a high level of toxicity, but also with the development of drug resistance in cancer cells 
[38]. 
Affymetrix array analysis and pathway analysis have been used to identify a list of 
genes associated with cell cycle control that are regulated by ethanol-based Ganoderma 
extracts. We have identified over 200 unique genes associated with cell cycle control that 
showed significant changes in their expression levels after treatment with ethanol-based 
Ganoderma extracts (Table 3). It is not feasible to examine and compare the expression 
levels of every single gene identified as being significantly differentially expressed in the 
Affymetrix  array  and  pathway  analysis.  Instead,  high-penetrance  genes  with  strong 
association  with  cancer  based  on  literature  findings  were  selected  to  undergo  further 
analysis. In particular, two genes, namely BRCA1 and CDKN3, which are known tumour 
suppressor genes (TSGs), were up-regulated by ethanol-based Ganoderma extracts. 
 
Genes associated with Cell cycle control: BRCA1 is a TSG involved in the repair of DNA 
damage and in the control of the cell cycle from G2 to M phase [39]. Various studies have 
identified BRCA1 as a major TSG in breast cancer and other cancer types, including cancer 
of the prostate [40, 41, 42]. The expression of BRCA1 in PC3 and DU145 was up-regulated 
after treatment with spore oil and Ganoderma ethanol extract. BRCA1 directly interacts and 
enhances the activity of androgen receptors (AR) and induces the expression of CDKNs, 
leading  to  increased  androgen-induced  cell  death  in  PCa  cells  [43,  44].  Therefore, 
overexpression of BRCA1 together with androgen stimulation via AR can inhibit cell cycle 
progression and increase apoptosis in PCa. Both PC3 and DU145 are aggressive androgen-
independent cell lines [45]. This suggests that BRCA1 inhibition of cell cycle progression 
via AR should not affect PC3 and DU145 cell lines. However, Alimirah et al. [46] have 
shown that both PC3 and DU145 still express low levels of AR. Therefore, up-regulation of 
BRCA1 followed by AR-dependent inhibition of cell cycle progression may be one of the 
biologically active pathways through which Ganoderma ethanol-based extracts exert their 
growth inhibitory effect in PC3 and DU145. 
Progression of the cell cycle is closely regulated by a series of cyclin-dependent kinase 
(CDK) and their inhibitors [47].  CDKN3 dephosphorylates and inhibits CDK2 which is 
essential for the G1/S transition of the cell cycle [48]. 
As  shown  in  Figure  2  the  expression  profiles  of  CDKN3  and  BRCA1  are  similar. 
Ganoderma ethanol extract induced a greater increase in gene expression than spore oil in 
DU145 and PC3 cell lines. Conclusions drawn from other studies which showed BRCA1 up-
regulated  expression  levels  of  CDK  inhibitors  suggest  that  CDKN3  may  be  one  of  the 
down-stream targets up-regulated by BRCA1 [49, 50]. 
 
A gene associated with DNA repair: RAD51 is involved in the repair of DNA double 
strand  breakages  [51].  Overexpression  of  RAD51  results  in  a  variety  of  consequences 
including increased resistance to DNA damaging agents, disruption of the cell cycle, and 
apoptotic cell death [51]. Overexpression of RAD51 is also associated with more aggressive Functional Foods in Health and Disease 2014; 4(5):182-207          Page 198 of 207 
 
forms of PCa [52]. Up-regulation of RAD51 may be beneficial for inhibiting earlier stages 
of PCa but can enhance progression of more aggressive forms of PCa. Alternately, it is also 
possible  that  the  observed  up-regulation  of  RAD51  is  simply  an  indication  of  genomic 
instability caused by inhibition of cell cycle as a result of Ganoderma administration [53]. 
 
Genes associated with Wnt/β-catenin signalling pathway: Both CDH11 and COL11A1 
are associated with the Wnt/β-catenin signalling pathway [54, 55, 56]. We have found that 
treatment of PC3 cells with Ganoderma ethanol-based extracts caused a significant increase 
in  the  expression  of  CDH11.  CDH11  is  involved  in  cell-cell  adhesion,  and  increased 
expression in tumours is associated with a reduced risk of metastasis [54]. Down-regulation 
of CDH11 expression via hyper-methylation of CDH11 genes is commonly observed in 
metastatic  cancers  [57].  Thus,  increased  CDH11  expression  could  promote  cell-cell 
adhesion of PC3 and reduce the risk of metastasis via cell detachments. 
Likewise,  our  results  have  indicated  that  treatment  of  PC3  cells  with  Ganoderma 
ethanol-based extracts caused a significantly reduced expression of COL11A1. COL11A1 is 
a  type  of  protein  which  forms  collagen  [58].  Collagen  is  a  major  substituent  of  the 
extracellular  matrix  (ECM),  and  its  degradation  in  tissue  is  associated  with  tumour 
aggressiveness and risk of metastasis [59]. Collagen levels in PCa tissues were found to be 
significantly  associated  with  Gleason  score,  a  system  used  to  determine  PCa  stage  and 
aggressiveness [58]. Studies have reported that increased COL11A1 expression is associated 
with more aggressive cancers, including PCa [58, 60].  
CDH11,  in  addition  to  cell-cell  adhesion,  may  also  be  involved  in  cell  cycle  and 
apoptosis  via  the  Wnt/β-catenin  signalling  pathway  [55].  The  Wnt/β-catenin  signalling 
pathway is often up-regulated in advanced cancer. The overexpression of this pathway has 
been  reported  as  being  related  to  drug-resistance  in  cancer,  as  well  as  epithelial–
mesenchymal transition, which promotes metastasis [61, 62]. Studies [54, 55] have reported 
that CDH11 acts as a tumour-suppressor and inhibits the Wnt/β-catenin signalling pathway. 
In  addition,  Fischer  et  al.  [56]  have  reported  that  in  colorectal  cancer,  with  overactive 
Wnt/β-catenin  signalling,  COL11A1  is  found  to  be  overexpressed.  This  suggests  that 
COL11A1 expression is associated with Wnt/β-catenin signalling. Furthermore, Jedinak et 
al. [63] have shown that an extract of G. lucidum can inhibit growth of colorectal cancer 
cell lines via reducing β-catenin expression. Wnt/β-catenin signalling is involved in the 
activation of β-catenin, which is degraded and inhibited by the Fas ligand [64]. PC3 is Fas-
sensitive and DU145 is Fas-resistant [65]. Therefore, the down-regulation of COL11A1 and 
up-regulation  of  CDH11,  which  is  only  observed  in  the  Fas-sensitive  PC3,  may  be 
associated  with  the  Fas-signalling  pathway.  The  down-regulation  of  COL11A1  and  up-
regulation of CDH11 are indicators of decreased cell proliferation and increased apoptosis 
via Wnt/β-catenin and Fas-signalling pathways. 
 
Immune response and inflammation: Treatment of PC3 and DU145 cancer cells with 
Ganoderma extracts containing polysaccharides (Ganoderma water extract and Ganopoly) 
resulted in changes in gene expression associated with immune response activity. Several 
studies have shown that Ganoderma polysaccharides can exert their anti-cancer activity via 
stimulating the host’s immune system [16, 66, 67]. However, as there are no immune cells 
present in cell culture, changes in immune activity does not explain the observed growth 
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Inflammatory response is closely associated with immune response and plays a role in 
the development and survival of cancer cells [68, 69]. Inflammation has been linked as a 
causal agent in around 20% of cancer cases [70, 71]. Men diagnosed with chronic prostatitis 
(inflammation of the prostate) have an increased risk of developing PCa, while men taking 
non-steroidal anti-inflammatory drugs (NSAIDs) for a prolonged period have a decreased 
risk of PCa [70, 71]. Therefore, it is possible that Ganoderma polysaccharides can directly 
affect the survival and proliferation of PCa cells via regulation of inflammation. In addition, 
chronic  inflammation  is  also  associated  with  a  host  of  diseases  other  than  cancer.  G. 
lucidum’s  ability  to  regulate  inflammation  may  contribute  to  its  wide  range  of  health 
benefits. 
In  this  study,  Affymetrix  array  analysis  and  pathway  analysis  have  been  used  to 
identify a list of genes affected by treatment with Ganoderma water extract and Ganopoly. 
Several  genes  which  are  significantly  associated  with  inflammation  were  affected  by 
treatment with the two extracts, which warrant further analysis. 
IL1α  was  down-regulated  in  PC3  cell  lines  treated  with  water-based  Ganoderma 
extracts.  IL1α  promotes  immune  responses  by  inducing  IL2  production  and  stimulates 
proliferation of other immune cells. IL1α also promotes a pro-inflammatory response by 
stimulating  the  release  of  prostaglandin  and  collagenase,  andpromotes  cell  survival  and 
angiogenesis  by  stimulating  production  of  growth  factors:  Vascular  endothelial  growth 
factor (VEGF), Interleukin 8 (IL8), Interleukin 6 (IL6), Tumour necrosis factor-α (TNF-α), 
and  Tumour  growth  factor-β  (TGF-β)  in  the  tumour  microenvironment,  and  further 
promotes metastatic activity by stimulating production of matrix metalloproteinase enzymes. 
IL1α is up-regulated in breast, colon, lung, head and neck cancers, and melanomas, and it is 
associated  with  more  aggressive  cancer  and  poorer  survival  [72].  Therefore,  down-
regulation of IL1α should reduce cancer aggressiveness. In this study, IFITM1 was found to 
be down-regulated in the DU145 cell line and up-regulated in the PC3 cell line. IFITM1 is 
crucial for the anti-proliferative action of IFN-γ either by inhibiting ERK activation or by 
arresting  cell  growth  in  the  G1  phase  in  a  p53-dependent  manner  [73].  PC3  cells  are 
sensitive to the anti-proliferative effect of IFN-γ, while DU145 is resistant [74]. The down-
regulation  in  gene  expression  levels  of  IFITM1  in  DU145  may  explain  why  DU145  is 
resistant to the anti-proliferative effects of IFN-γ. 
We have found the expression of IL24 to be strongly up-regulated by Ganopoly in 
DU145.  Some  probes  of  IL24  were  also  found  to  be  increased  in  PC3  treated  with 
Ganoderma water-based extracts. IRF1 has similar expression profiles to IL24. Both IL24 
and IRF1 are TSGs and exert anti-cancer activities via activation of STAT1 and STAT3 
transcription factors [75, 76, 77, 78]. Up-regulation of IL24 and IRF1 has anti-proliferative 
effects in breast and colon cancers [75, 76, 77, 78]. Due to the variation between the probe 
expression levels of the above mentioned two genes in Ganopoly treated DU145 (between a 
2 to 40-fold increase), we cannot determine the exact level of up-regulation exerted by 
Ganopoly. In addition, for PC3 treated with Ganoderma water extract, only one out of three 
probes  showed  significant  up-regulation,  while  the  other  two  probes  showed  non-
statistically significant changes. Affymetrix array analysis showed evidence that treatment 
of Ganoderma water extract increased expression of IL24 which promotes growth inhibition 
of cancers. 
We have found the expression of S100A9 to be down-regulated after treatment with 
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PCa [79]. However, S100A9 is not expressed in healthy prostate tissues [80]. Its expression 
is  induced  by  hypoxia,  which  is  common  in  tumours  [81].  The  up-regulated  S100A9 
expression promotes inflammation via up-regulation of IL8 [82]. Therefore, the observed 
down-regulation of S100A9 can potentially reduce inflammation and may be the cause of 
the down-regulation of other pro-inflammatory cytokines observed in other studies after 
treatment of Ganoderma extracts [83, 84, 85]. 
 
Comparison  of  gene  expression  levels  between  RT-PCR  and  Affymetrix:  The  gene 
expression levels obtained from RT-PCR analysis were compared to the gene expression 
levels from Affymetrix analysis. For water-based extracts (Ganoderma water extract and 
Ganopoly), we compared the gene expression levels of S100A9, IFITM1, IL1α, IL24, and 
IRF1 between RT-PCR and Affymetrix array and found similar expression profiles (Figure 
7).  For  ethanol-based  extracts  (Ganoderma  ethanol  extract  and  spore  oil  extract),  we 
compared the gene expression levels of CDKN3, RAD51, CDH11, and BRCA1 between RT-
PCR  and  Affymetrix  array  (Figure  8).  Likewise,  we  found  similar  expression  profiles. 
Overall,  a  comparison  between  RT-PCR  and  Affymetrix  array  analyses  showed  similar 
expression  profiles.  However  a  greater  fold  change  was  observed  in  TR-PCR  than 
Affymetrix. This may be due to the inclusion of only one housekeeping gene for reference 
in the RT-PCR analysis. Therefore, we can conclude that the results from RT-PCR support 
the result from Affymetrix array analyses, at least in terms of whether a gene is up- or 
down-regulated. 
 
CONCLUSIONS 
Utilizing IC50 tissue culture, we have found that the ethanol-based Ganoderma extracts 
have stronger growth inhibitory effects than extracts obtained with water-based extraction 
methods.  In  particular,  the  extract  of  Ganoderma  spore  oil  showed  the  greatest  growth 
inhibitory activity when compared to the other extracts tested. This suggests that the section 
of G. lucidum which contains the highest level of anti-cancer active ingredients may be its 
spores.  However,  other  extracts  tested  in  this  study  also  showed  significant  growth 
inhibitory activities through different biologically active pathways, thus their anti-cancer 
potential should not be disregarded. 
Utilizing  Affymetrix  array  analysis,  we  have  identified  several  biologically  active 
pathways associated with the growth inhibitory activity of Ganoderma extracts on PCa cell 
lines. Several key genes that are associated with cancer suppression and progression were 
found to be influenced by Ganoderma extracts. These findings are supported in the literature 
to be significantly associated with cancer development and progression. Examination of the 
protein expression of these genes, using Western blot, could further validate and support our 
results from the Affymetrix array analysis. Additional investigations into other key genes 
associated  with  the  anti-cancer  activities  of  Ganoderma  would  provide  a  broader 
understanding of the anti-cancer functions of Ganoderma. Moreover, further analysis of the 
wealth of data generated via Affymetrix array analysis may identify novel pathways and 
interaction of genes associated with cancer pathology. In the modern era of “personalized 
medicine,” the identification of anti-cancer and anti-inflammatory activities of G. lucidum 
can promote its use in humans, both as a supplement to improve health and as therapy for 
the treatment and prevention of cancer. Functional Foods in Health and Disease 2014; 4(5):182-207          Page 201 of 207 
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BRCA1  Breast Cancer type 1 
CDH11  Cadherin 11, type 2 
CDK 2  Cyclin-dependent kinase 2 
CDKN3  Cyclin-dependent kinase inhibitor 3 
COL11A1  Collagen, type XI, alpha 1 
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GAPDH  Glyceraldehyde 3-phosphate dehydrogenase 
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IFITM1  interferon induced transmembrane protein 1 
IL1α  interleukin 1-alpha 
IL24  interleukin 24 
IL6  Interleukin 6 
IL8  Interleukin 8 
IRF1  interferon regulatory factor 1 
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RT-PCR  real time - polymerase chain reaction 
S100A9  S100 calcium binding protein A9 
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